A Phase 3 interventional study of DLBS3233 and Metformin XR in Polycystic Ovary Syndrome (PCOS) and Insulin Resistance, sponsored by Dexa Medica Group. Completed at 7 sites in Indonesia. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing metformin in Polycystic Ovary Syndrome — 9 open to participants now, 11 under way, 3 of them phase 3. Metformin · Polycystic Ovary Syndrome.
Among the 114 studies testing metformin in Polycystic Ovary Syndrome, this one is the 17th largest by enrollment of the 113 interventional ones that give a count, is one of 6 that started in 2014, is one of 18 in phase 3, and was the 52nd registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →9 of the 114 studies testing metformin in Polycystic Ovary Syndrome are open now, in 11 countries. Recruiting first, the newest first:
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Future University in Egypt · Sites in Egypt
Ages 18–40 · Women only
Shanghai 10th People's Hospital · Sites in China
Ages 18–45 · Women only
Fundació Sant Joan de Déu · Sites in Austria, Denmark, Italy and 3 more countries
Ages 12–23 · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 13 · Phase 3 21 · Phase 4 33
First in 1997; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 75 across the 113 interventional studies. Of the 78 that completed or were terminated, 12 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 114 have an industry lead sponsor. The 10 most frequent:
Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.
Dexa Medica Group has 2 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies testing metformin in Polycystic Ovary Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07604779Beni-Suef UniversityEnhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection | 2026-12-03 |
| NCT05680805Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshMetabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS | 2026-12-30 |
| NCT07770711Dicle UniversityInositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 114 studies testing metformin in Polycystic Ovary Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.
There will be 3 groups of treatment (N = 186), each consist of 62 subjects, as the following:
Laboratory examination to evaluate metabolic efficacy parameters will be performed at baseline, Month 3rd, and end of study (Month 6th).
Clinical and laboratory examination to evaluate the reproductive efficacy parameters using trans-vaginal USG and biomarkers (such as reproductive hormones) will be performed at baseline to the end of study.
Safety examination will be performed at baseline and end of study. Occurrence of adverse event will be observed along the study conduct.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the following (Rotterdam Criteria):
Exclusion Criteria:
Based on previous or current medical (either laboratory or clinical) examination, subjects known to have any of the following conditions:
Known to have the following medical condition:
Have been regularly taking any of the following medications, within ≤ 3 months prior to screening, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
Drug: DLBS3233 · Drug: Placebo metformin
Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
Drug: Metformin XR · Drug: Placebo DLBS3233
DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
Drug: DLBS3233 · Drug: Metformin XR
Also known as: Inlacin
Also known as: Glumin XR
Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
HOMA-IR reduction
HOMA-IR reduction from baseline to Month 6th (end of study)
Time frame: 6 months
Lipid profile improvement
Lipid profile improvement (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides level) from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
Improvement of glucose tolerance
Improvement of glucose tolerance (reduction of FPG and 2-hour PPPG) from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
Change of waist circumference
1, 2, 3, 4, 5, and 6 months
Time frame: 1, 2, 3, 4, 5, and 6 months
Response rate: presence of ovulation
Presence of ovulation will be evaluated using trans-vaginal USG to find dominant follicle(s), at the day/period of ovulation, starting from menstrual cycle of Month 3rd up to Month 6th. Measurement of progesterone level will be performed 7 days after the finding of dominant follicle on USG examination to confirm the presence of ovulation.
Time frame: menstrual cycle of Month 3rd up to that of Month 6th
Change of endometrium thickness
Change of endometrium thickness will be measured by using trans-vaginal USG at basal condition and at the day/period of ovulation
Time frame: 3 to 6 months
Improvement of S/A ratio
Improvement from baseline of the S/A ratio (defined as the ratio between stromal and total area of median ovarian section) will be measured using trans-vaginal USG (trans-longitudinal measurement) at Baseline, menstrual cycle of Month 3rd, and menstrual cycle of Month 6th at basal condition.
Time frame: 3 to 6 months
Improvement in Ferriman-Gallwey Score
Improvement in Ferriman-Gallwey Score from baseline to Month 3rd and Month 6th (the end of study)
Time frame: 3 and 6 months
Reduction of free testosterone level
Reduction of free testosterone level from baseline to Month 6th (end of study)
Time frame: 6 months
Change of luteinizing hormone (LH) level
Change of luteinizing hormone (LH) level from baseline to Month 6th (end of study)
Time frame: 6 months
Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio
Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio from baseline to Month 6th (end of study)
Time frame: 6 months
Liver function
Liver function (levels of serum AST, ALT, alkaline phosphatase) will be measured at baseline and Month 6th (end of study)
Time frame: 6 months
Renal function
Renal function (levels of serum creatinine, BUN) will be measured at baseline and Month 6th (end of study)
Time frame: 6 months
Number of adverse events and subjects with events
Adverse events as well as number of events and subjects experiencing the events will be observed and evaluated throughout study period (6 months) and until all adverse events have been recovered or stabilized
Time frame: During 6 months
The record gives a start of Oct 2014, a primary completion of Feb 2019 and a completion of May 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: DLBS3233 · Metformin